Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2006 March;52(1) > Minerva Gastroenterologica e Dietologica 2006 March;52(1):47-52

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  AN UPDATE ON HEPATITIS B VIRUS INFECTION


Minerva Gastroenterologica e Dietologica 2006 March;52(1):47-52

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

Prevention of intrahepatic hepatocarcinoma recurrence in patients with viral cirrhosis: two potential options

Tabone M. 1, 2, Pellicano R. 3

1 Unit of Gastroenterology Mauriziano Umberto I Hospital, Turin, Italy 2 Unit of Gastroenterology Institute for Cure and Cancer Research Candiolo, Turin, Italy 3 Unit of Gastroenterology and Liver Diseases San Giovanni Battista Hospital, Turin, Italy


PDF  


Mortality due to hepatocellular carcinoma (HCC) is still high, because of its development in liver with impaired function due to underlying cirrhosis, of its chemoresistance and of its high rate of recurrence. Liver transplantation is considered the most efficacious treatment for patients with HCC. However, the low availability of organs limits the offer of this option to all candidates. Furthermore, liver transplantation is not lacking in risk of tumour recurrence. Other curative options include surgical resection and ablation using percutaneous techniques. Such approaches give similar and satisfactory survival rates, providing that patient selection is optimal in terms of tumour size and liver function. Since even in the presence of a radical therapeutic result this cancer maintains a high tendency for local recurrence, it is very important to explore the adjuvant ways to increase the disease-free survival in patients surgically treated. Treatment with interferon a and intrahepatic injection of 131-Iodine labelled lipiodol (131I-Lipiodol) are instead showing encouraging results. This review presents a concise update on this issue.

top of page

Publication History

Cite this article as

Corresponding author e-mail